Novel circulating tumor DNA (ctDNA) based ddPCR drop-off assays for improved Minimal Residual Disease (MRD) monitoring in Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Rausch, C. [1 ]
Ziemann, F. [1 ]
Schneider, S. [1 ]
Subklewe, M. [1 ]
Spiekermann, K. [1 ]
Rothenberg-Thurley, M. [1 ]
Metzeler, K. H. [1 ]
机构：
[1] Ludwig Maximilian Univ Munchen, Lab Leukamiediagnost, Univ Klinikum, Med Klin & Poliklin 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P920
引用
收藏
页码：252 / 252
页数：1
相关论文
共 50 条
  • [31] Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM study group
    Langebrake, Claudia
    Creutzig, Ursula
    Dworzak, Michael
    Hrusak, Ondrej
    Mejstrikova, Ester
    Griesinger, Frank
    Zimmermann, Martin
    Reinhardt, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3686 - 3692
  • [32] A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
    Onecha, Esther
    Linares, Maria
    Rapado, Inmaculada
    Ruiz-Heredia, Yanira
    Martinez-Sanchez, Pilar
    Cedena, Teresa
    Pratcorona, Marta
    Perez Oteyza, Jaime
    Herrera, Pilar
    Barragan, Eva
    Montesinos, Pau
    Garcia Vela, Jose Antonio
    Magro, Elena
    Anguita, Eduardo
    Figuera, Angela
    Riaza, Rosalia
    Martinez-Barranco, Pilar
    Sanchez-Vega, Beatriz
    Nomdedeu, Josep
    Gallardo, Miguel
    Martinez-Lopez, Joaquin
    Ayala, Rosa
    HAEMATOLOGICA, 2019, 104 (02) : 288 - 296
  • [33] Minimal residual disease (MRD) analysis in acute myeloid leukemia (AML) with normal karyotype carrying NPM1 gene mutations
    Agueli, C.
    La Rosa, M.
    Fabbiano, F.
    Rizzo, V
    Cascio, L.
    Cammarata, G.
    Marfia, A.
    Bica, M. G.
    Mirto, S.
    Santoro, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 169 - 169
  • [34] Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
    Perea, G
    Lasa, A
    Aventín, A
    Domingo, A
    Villamor, N
    de Llano, MPQ
    Llorente, A
    Juncà, J
    Palacios, C
    Fernández, C
    Gallart, M
    Font, L
    Tormo, M
    Florensa, L
    Bargay, J
    Martí, JM
    Vivancos, P
    Torres, P
    Berlanga, JJ
    Badell, I
    Brunet, S
    Sierra, J
    Nomdedéu, JF
    LEUKEMIA, 2006, 20 (01) : 87 - 94
  • [35] Minimal residual disease (MRD) detection strategy in acute myeloid leukemia (AML). A six-color study on 27 consecutive cases
    Gorrese, M.
    Abate, G.
    Pascariello, C.
    Raia, M.
    Scalia, G.
    Mirabelli, P.
    Mariotti, E.
    Di Noto, R.
    Camera, A.
    Del Vecchio, L.
    CYTOMETRY PART A, 2008, 73A (01) : 82 - 82
  • [36] Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
    G Perea
    A Lasa
    A Aventín
    A Domingo
    N Villamor
    M Paz Queipo de Llano
    A Llorente
    J Juncà
    C Palacios
    C Fernández
    M Gallart
    L Font
    M Tormo
    L Florensa
    J Bargay
    J M Martí
    P Vivancos
    P Torres
    J J Berlanga
    I Badell
    S Brunet
    J Sierra
    J F Nomdedéu
    Leukemia, 2006, 20 : 87 - 94
  • [37] Presence of Post Induction Minimal Residual Disease (MRD) Is an Independent Predictor for Relapse and Is Associated with Inferior Survival in Acute Myeloid Leukemia (AML)
    Teo, Winnie Z. Y.
    Seah, Elaine
    Lee, Shir Ying
    Liu, Te-Chih
    Chng, Wee-Joo
    Ng, Chin Hin
    BLOOD, 2017, 130
  • [38] Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238
    Syeda, Mahrukh M.
    Wiggins, Jennifer M.
    Alegun, Josephine
    Ali, Saim
    Mandal, Soutrik
    Tang, Tracy
    Desai, Keyur
    Dolfi, Sonia
    Tenney, Daniel J.
    Ascierto, Paolo A.
    Larkin, James
    Del Vecchio, Michele
    Weber, Jeffrey S.
    Polsky, David
    CLINICAL CANCER RESEARCH, 2024, 30 (21)
  • [39] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.
    Mehler, Shoshana
    Guilbeau, Seth
    Somer, Shmuel
    Reed, Kevin
    Greene, Heather
    Vaena, Daniel A.
    Grothey, Axel
    Somer, Brad
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [40] RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
    Kim, Taehyung
    Moon, Joon Ho
    Ahn, Jae-Sook
    Tyndel, Marc S.
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Jung, Sung-Hoon
    Yang, Deok-Hwan
    Lee, Je-Jung
    Choi, Seunghyun
    Lee, Ja-yeon
    Lee, Yoojin
    Sohn, Sang Kyun
    Zhang, Zhaolei
    Kim, Hyeoung-Joon
    Kim, Dennis Dong Hwan
    BLOOD, 2018, 132
12345